KU Leuven

Imcyse SA is a clinical-stage biopharmaceutical company based in Liège, Belgium, specializing in innovative immunotherapeutic solutions aimed at treating severe chronic autoimmune diseases. Founded in 2010, Imcyse is pioneering a unique technology platform that employs Imotopes™, specifically modified peptides that target immune cells responsible for organ damage. This approach facilitates the generation of cytolytic CD4 T-cells, which selectively eliminate antigen-presenting cells and autoantigen-specific lymphocytes, thereby addressing diseases with limited treatment options. The company has shown proof of concept across various indications and has completed its initial clinical trial for type 1 diabetes, yielding promising outcomes. In addition to type 1 diabetes, Imcyse is actively developing a pipeline of therapies for multiple autoimmune diseases, aiming to provide effective treatment while preserving overall immune defense.

reMYND NV is a biotechnology company based in Leuven, Belgium, focused on developing disease-modifying treatments for neurodegenerative and metabolic disorders, including Alzheimer’s, Parkinson’s, and diabetes. The company is known for its investigational compounds, such as ReS19-T, aimed at treating Alzheimer’s, and ReS39, which targets diabetes. Additionally, reMYND is advancing ReS3-T, a program that addresses both Alzheimer’s and epilepsy by regulating neuronal activity. The company utilizes a phenotypic screening platform to discover small molecule treatments that counteract the toxicity of misfolded proteins associated with these diseases. As a contract research organization (CRO), reMYND also assists clients, including major pharmaceutical companies in the United States, Europe, and Japan, by providing in-vivo assessments of experimental treatments using proprietary mouse models. Founded in 2002, reMYND has established a reputation for delivering pivotal proof-of-concept data that supports drug development in protein misfolding disorders.

ViroVet is an innovative company focused on developing advanced technologies to combat viral diseases in livestock. Its product pipeline includes antiviral drugs targeting respiratory disease complexes and novel vaccines for swine viral infections. Given the substantial economic impact of viral diseases, which cost the livestock industry billions annually, ViroVet aims to provide effective solutions that can be used independently or alongside existing vaccines and biosecurity measures. The company addresses the growing demand for animal protein amid increasing global population and livestock density, as well as climate change challenges that heighten the risk of viral outbreaks. ViroVet has garnered support from key opinion leaders in livestock medicine, who recognize the potential of its products to transform the industry, notably by reducing antibiotic usage and enhancing overall animal health and productivity.

Montis Biosciences is a biotechnology company founded in 2020 and based in Meise, Belgium. The company focuses on developing innovative immune-oncology therapeutics that address the intersection of vascular dysfunction and immune suppression in the treatment of solid tumors. Montis Biosciences has created a proprietary target screening and assay platform aimed at modulating the interactions between tumor endothelial cells and perivascular macrophages. This research provides valuable insights into the cellular dynamics of these interactions, enabling the development of novel therapeutic strategies to enhance immune responses against various tumors.

MyCellHub is a pre-startup based in KULeuven that operates within the biotherapeutics industry, focusing on optimizing cell production processes. The company has developed a regulatory compliant software-as-a-service platform that digitalizes laboratory and cleanroom workflows, specifically tailored for manufacturing environments. This platform enables users to capture real-time data from various sources and integrates seamlessly with existing ERP systems. By providing actionable insights through cell culture-specific process analytics, MyCellHub enhances manufacturing efficiency and facilitates regulatory compliance by maintaining a real-time audit trail and automated batch records. Overall, MyCellHub aims to transform traditional production methodologies in the biotherapeutics sector.

nextAuth is a developer of mobile-based user authentication software that enhances security while ensuring a seamless user experience. The company's innovative technology allows users to authenticate their identity using their mobile phones, eliminating the need for traditional usernames and passwords. This approach not only simplifies the login process for web portals and applications but also supports secure document signing and transactions that meet the standards for advanced electronic signatures. By leveraging advanced cryptography, nextAuth addresses the challenge of balancing usability and security, providing a robust multi-factor authentication solution for users.

reMYND NV is a biotechnology company based in Leuven, Belgium, focused on developing disease-modifying treatments for neurodegenerative and metabolic disorders, including Alzheimer’s, Parkinson’s, and diabetes. The company is known for its investigational compounds, such as ReS19-T, aimed at treating Alzheimer’s, and ReS39, which targets diabetes. Additionally, reMYND is advancing ReS3-T, a program that addresses both Alzheimer’s and epilepsy by regulating neuronal activity. The company utilizes a phenotypic screening platform to discover small molecule treatments that counteract the toxicity of misfolded proteins associated with these diseases. As a contract research organization (CRO), reMYND also assists clients, including major pharmaceutical companies in the United States, Europe, and Japan, by providing in-vivo assessments of experimental treatments using proprietary mouse models. Founded in 2002, reMYND has established a reputation for delivering pivotal proof-of-concept data that supports drug development in protein misfolding disorders.

Loci Orthopaedics Limited, established in 2017 and headquartered in Upper Newcastle, Ireland, specialises in the manufacture of medical instruments, notably the InDx implant. This innovative device is designed to mimic natural thumb joint motions and offers a less invasive surgical solution for patients with arthritis in their thumb base joint, addressing a significant unmet clinical need in orthopaedics.

UgenTec, based in Hasselt at the Corda Campus, is a rapidly growing company specializing in molecular diagnostics software. The company has garnered multiple awards for its innovative approach and advanced algorithm technologies. UgenTec delivers an independent diagnostic platform designed to aid molecular laboratories in their DNA (PCR) analyses. Its software intelligently analyzes raw PCR data from various commercial devices, enabling standardized, automated, and certified interpretation of PCR assays. This allows lab technicians to significantly reduce sample analysis time from 1.5 hours to just 3 minutes, all while enhancing reliability. By improving laboratory efficiency and providing greater diagnostic certainty for patients, UgenTec stands out in the molecular diagnostics market.

VersaSense is a company based in Leuven, Belgium, specializing in wireless fabric technology for industrial sensing and control systems. Its platform integrates software, networking, and hardware components, allowing clients to connect various assets to cloud analytics platforms and manage their infrastructure effectively. This capability enables organizations in sectors such as industry, consumer goods, technology, and agriculture to securely transmit sensor data to IoT platforms and enterprise back-end systems. By providing these services, VersaSense helps clients reduce the total cost of ownership associated with their industrial sensing and control needs, while also offering professional support and integration services.

Porphyrio NV, based in Leuven, Belgium, specializes in the development of advanced management systems for poultry farming. The company offers two primary products: Lay-Insight, which focuses on the management of egg production, and Broiler-Insight, designed for broiler production management. Porphyrio’s technology is tailored for various types of poultry, including breeders, laying hens, broilers, and turkeys. Its innovative systems leverage real-time data and advanced statistical algorithms to enhance operational efficiency and provide proactive early warnings, enabling farm managers to optimize their production processes. Additionally, Porphyrio’s solutions integrate access control, video surveillance, and connectivity with external enterprise resource planning systems, providing comprehensive support for livestock management. Since November 2018, Porphyrio has operated as a subsidiary of Evonik Industries AG, further solidifying its position in the agricultural technology sector.